This review aims to provide current evidence on CDK4/6 inhibitors in HR+/HER2- breast cancer, highlighting their mechanisms, interaction with endocrine resistance, combination strategies, and emerging biomarkers guiding personalized therapy. This evidence concerns the gene CDK4 and breast carcinoma.